A Multicenter Phase II Study of S-1 for Gemcitabine-Refractory Biliary Tract Cancer

Cancer Chemotherapy and Pharmacology - Germany
doi 10.1007/s00280-013-2106-0
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Multicenter Phase II Study of Oxaliplatin, Irinotecan, and S-1 as First-Line Treatment for Patients With Recurrent or Metastatic Biliary Tract Cancer

Cancer Research and Treatment
Cancer ResearchOncology
2018English

A Phase II Trial of Fixed-Dose Rate Gemcitabine Plus Capecitabine in Metastatic/Advanced Biliary Tract Cancer Patients

Oncology
MedicineCancer ResearchOncology
2012English

S‐1 Plus Raltitrexed for Refractory Metastatic Colorectal Cancer: A Phase II Trial

Oncologist
Cancer ResearchMedicineOncology
2019English

Gemcitabine and Oxaliplatin (GEMOX) in Gemcitabine Refractory Advanced Pancreatic Adenocarcinoma: A Phase II Study

British Journal of Cancer
Cancer ResearchOncology
2006English

A Multicentre Randomised Phase II Trial of Gemcitabine Alone vs Gemcitabine and S-1 Combination Therapy in Advanced Pancreatic Cancer: GEMSAP Study

British Journal of Cancer
Cancer ResearchOncology
2012English

Irinotecan Plus Gemcitabine and Fluorouracil in Advanced Biliary Tract Cancer: A Retrospective Study

Digestion
Gastroenterology
2016English

Single Agent Gemcitabine in Refractory or Relapsed Small-Cell Lung Cancer. Phase II Study

Research in Oncology
2007English

A Phase II Study of Gemcitabine Monotherapy in Breast Cancer Patients Refractory to Anthracycline and Taxane

Cancer Research and Treatment
Cancer ResearchOncology
2002English

A Phase I Study of Neoadjuvant Chemotherapy With Gemcitabine Plus Oral S-1 for Resectable Pancreatic Cancer

Molecular and Clinical Oncology
Cancer ResearchOncology
2013English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy